266P Discontinuation rate and serious adverse events of chemoimmunotherapy as neoadjuvant treatment for triple-negative breast cancer: A systematic review and meta-analysis
Francesca Matilde Schipilliti(Azienda Ospedaliera Sant'Andrea), Mario Giuliano(Regione Campania), Francesco Di Costanzo, Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Filippo Montemurro(Roche (Switzerland)), Grazia Arpino(University of Naples Federico II), Lucia Del Mastro(Ospedale Policlinico San Martino), Fabio Puglisi(University of Udine), Silvana Acquafredda(Istituto Tumori Bari), Alessandro Rizzo(Istituto Tumori Bari)
Cited by 0
Related Papers
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
|Journal of Clinical Oncology|2010|887
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830